{
  "ticker": "CRSP",
  "company_name": "CRISPR Therapeutics AG",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04438083",
      "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Renal Cell Carcinoma",
      "start_date": "2020-06-16",
      "completion_date": "2024-10-08",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT06208878",
      "title": "A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "",
      "condition": "Hematologic Malignancy, Solid Malignancy",
      "start_date": "2023-11-22",
      "completion_date": "2038-08",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT05210530",
      "title": "An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases",
      "start_date": "2022-01-24",
      "completion_date": "2023-01-19",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT04502446",
      "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "T Cell Lymphoma",
      "start_date": "2020-07-31",
      "completion_date": "2024-08-30",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT05795595",
      "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma",
      "start_date": "2023-03-13",
      "completion_date": "2025-09-18",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT04035434",
      "title": "A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL",
      "start_date": "2019-07-22",
      "completion_date": "2024-10-04",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT05565248",
      "title": "An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases",
      "start_date": "2023-01-20",
      "completion_date": "2025-08",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT04244656",
      "title": "A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma",
      "start_date": "2020-01-22",
      "completion_date": "2024-01-04",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    },
    {
      "nct_id": "NCT05643742",
      "title": "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma",
      "start_date": "2023-03-10",
      "completion_date": "2030-02",
      "enrollment": 0,
      "sponsor": "CRISPR Therapeutics AG"
    }
  ],
  "summary": {
    "total_trials": 9,
    "by_phase": {
      "PHASE1": 4,
      "": 1,
      "PHASE1, PHASE2": 4
    },
    "by_status": {
      "TERMINATED": 4,
      "ENROLLING_BY_INVITATION": 1,
      "COMPLETED": 2,
      "RECRUITING": 2
    },
    "active_trials": 3,
    "completed_trials": 2,
    "conditions": [
      "B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma",
      "B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL",
      "Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma",
      "Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases",
      "Hematologic Malignancy, Solid Malignancy",
      "Multiple Myeloma",
      "Renal Cell Carcinoma",
      "T Cell Lymphoma"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:43.922689",
    "search_query": "CRISPR Therapeutics AG",
    "url": "https://clinicaltrials.gov/search?term=CRISPR+Therapeutics+AG"
  }
}